Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Other financing activities (2020 - 2025)

Historic Other financing activities for Gain Therapeutics (GANX) over the last 4 years, with Q3 2025 value amounting to $460793.0.

  • Gain Therapeutics' Other financing activities rose 3090.08% to $460793.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 1163.92%. This contributed to the annual value of $2.3 million for FY2024, which is 2916.28% down from last year.
  • Gain Therapeutics' Other financing activities amounted to $460793.0 in Q3 2025, which was up 3090.08% from $530499.0 recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Other financing activities ranged from a high of $1.4 million in Q2 2024 and a low of $213795.0 during Q2 2021
  • Over the past 3 years, Gain Therapeutics' median Other financing activities value was $423145.0 (recorded in 2025), while the average stood at $527171.0.
  • Examining YoY changes over the last 5 years, Gain Therapeutics' Other financing activities showed a top increase of 5065.67% in 2025 and a maximum decrease of 6297.62% in 2025.
  • Over the past 3 years, Gain Therapeutics' Other financing activities (Quarter) stood at $213795.0 in 2021, then skyrocketed by 92.18% to $410871.0 in 2024, then grew by 12.15% to $460793.0 in 2025.
  • Its Other financing activities was $460793.0 in Q3 2025, compared to $530499.0 in Q2 2025 and $423145.0 in Q1 2025.